(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 13.54% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Ani Pharmaceuticals's revenue in 2025 is $674,068,000.On average, 6 Wall Street analysts forecast ANIP's revenue for 2025 to be $18,319,888,344, with the lowest ANIP revenue forecast at $18,100,712,886, and the highest ANIP revenue forecast at $18,871,227,914. On average, 6 Wall Street analysts forecast ANIP's revenue for 2026 to be $19,821,342,045, with the lowest ANIP revenue forecast at $19,378,767,051, and the highest ANIP revenue forecast at $20,219,033,510.
In 2027, ANIP is forecast to generate $21,389,796,111 in revenue, with the lowest revenue forecast at $20,121,771,422 and the highest revenue forecast at $22,349,701,436.